Literature DB >> 18465317

The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise.

Susanne Møller1, Maj-Britt Jensen, Bent Ejlertsen, Karsten D Bjerre, Martin Larsen, Hanne B Hansen, Peer Christiansen, Henning T Mouridsen.   

Abstract

Introduction. Since 30 years, DBCG (Danish Breast Cancer Cooperative Group) has maintained a clinical database allowing the conduct of quality control studies, of randomised trials, examination of the epidemiology of breast cancer and of prognostic and predictive factors. Material and methods. The original database included patients with invasive breast cancer, but has later been expanded to patients with in situ breast cancer and hereditary breast and ovarian cancer families. Results. The multidisciplinary cooperative group has provided successive treatment guidelines and 70% of the 77284 registered patients have been enrolled and received treatment according to these guidelines. The standard treatments and the randomised trials included in the DBCG programmes are all briefly described. Among high-risk patients 48% have participated in randomised trials, and the results of these trials have largely been implemented in the next generation of treatment guidelines. Records within the clinical database of archival tumour tissue have established a basis for translational research and epidemiologic research has been enabled through linkage to other healthcare registries. Discussion. The joint conception of the multidisciplinary breast cancer group and a clinical database has provided improvements in the management of breast cancer patients and has enabled recruitment of patients onto randomised trials.

Entities:  

Mesh:

Year:  2008        PMID: 18465317     DOI: 10.1080/02841860802059259

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  72 in total

1.  Malignant melanoma, breast cancer and other cancers in patients with Parkinson's disease.

Authors:  Kathrine Rugbjerg; Søren Friis; Christina Funch Lassen; Beate Ritz; Jørgen H Olsen
Journal:  Int J Cancer       Date:  2012-03-22       Impact factor: 7.396

2.  Predictive pharmacogenetic biomarkers for breast cancer recurrence prevention by simvastatin.

Authors:  Thomas P Ahern; Per Damkier; Søren Feddersen; Anders Kjærsgaard; Timothy L Lash; Stephen Hamilton-Dutoit; Cathrine Bredal Lythjohan; Bent Ejlertsen; Peer M Christiansen; Deirdre P Cronin-Fenton
Journal:  Acta Oncol       Date:  2020-04-30       Impact factor: 4.089

3.  Functional polymorphisms in UDP-glucuronosyl transferases and recurrence in tamoxifen-treated breast cancer survivors.

Authors:  Thomas P Ahern; Mariann Christensen; Deirdre P Cronin-Fenton; Kathryn L Lunetta; Håvard Søiland; Jennifer Gjerde; Jens Peter Garne; Carol L Rosenberg; Rebecca A Silliman; Henrik Toft Sørensen; Timothy L Lash; Stephen Hamilton-Dutoit
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-07-12       Impact factor: 4.254

4.  Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study.

Authors:  Thomas P Ahern; Lars Pedersen; Maja Tarp; Deirdre P Cronin-Fenton; Jens Peter Garne; Rebecca A Silliman; Henrik Toft Sørensen; Timothy L Lash
Journal:  J Natl Cancer Inst       Date:  2011-08-02       Impact factor: 13.506

5.  Use of β-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and risk of breast cancer recurrence: a Danish nationwide prospective cohort study.

Authors:  Gitte Vrelits Sørensen; Patricia A Ganz; Steven W Cole; Lars A Pedersen; Henrik Toft Sørensen; Deirdre P Cronin-Fenton; Jens Peter Garne; Peer M Christiansen; Timothy L Lash; Thomas P Ahern
Journal:  J Clin Oncol       Date:  2013-05-06       Impact factor: 44.544

6.  An empiric modification to the probabilistic record linkage algorithm using frequency-based weight scaling.

Authors:  Vivienne J Zhu; Marc J Overhage; James Egg; Stephen M Downs; Shaun J Grannis
Journal:  J Am Med Inform Assoc       Date:  2009-06-30       Impact factor: 4.497

7.  Pak1, adjuvant tamoxifen therapy, and breast cancer recurrence risk in a Danish population-based study.

Authors:  Thomas P Ahern; Deirdre P Cronin-Fenton; Timothy L Lash; Henrik Toft Sørensen; Anne Gulbech Ording; Stephen J Hamilton-Dutoit; Ylva Hellberg
Journal:  Acta Oncol       Date:  2016-04-08       Impact factor: 4.089

8.  Participation in questionnaire studies among couples affected by breast cancer.

Authors:  Helene Terp; Nina Rottmann; Pia Veldt Larsen; Mariët Hagedoorn; Henrik Flyger; Niels Kroman; Christoffer Johansen; Susanne Dalton; Dorte Gilså Hansen
Journal:  Support Care Cancer       Date:  2014-12-10       Impact factor: 3.603

9.  Expression of survivin does not appear to influence breast cancer recurrence risk.

Authors:  Lindsay J Collin; Deirdre P Cronin-Fenton; Thomas P Ahern; Kristina B Christensen; Per Damkier; Stephen Hamilton-Dutoit; Anders Kjaersgaard; Kristina L Lauridsen; Rami Yacoub; Peer Christiansen; Henrik Toft Sørensen; Timothy L Lash
Journal:  Acta Oncol       Date:  2018-10-23       Impact factor: 4.089

10.  Multi-drug resistance protein 2 (MRP2) expression, adjuvant tamoxifen therapy, and risk of breast cancer recurrence: a Danish population-based nested case-control study.

Authors:  Cathrine F Hjorth; Anja S Nielsen; Henrik T Sørensen; Timothy L Lash; Per Damkier; Stephen Hamilton-Dutoit; Deirdre Cronin-Fenton
Journal:  Acta Oncol       Date:  2018-11-20       Impact factor: 4.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.